




The relative strengths and weaknesses of Amylin Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amylin Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 109% points. The greatest weakness of Amylin Pharmaceuticals INC is the variable Other Expenses, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 347%, being 112% points above the market average of 234%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	421,190	Assets	1,870,199
Cost of Goods Sold	0	Liabilities	296,017
Intangible Assets	0	Expenses	1,142,137
Liabilities, Current	296,017	Revenues	650,678
Liabilities, Non-Current	0	Stockholders Equity	1,574,182
Other Assets	617,847	Net Income	-543,399
Other Compr. Net Income	0	Comprehensive Net Income	-543,399
Other Expenses	709,698	BaseVar	2,005,486
Other Liabilities	0	ECR before LimitedLiability	267%
Other Net Income	-51,940	Economic Capital Ratio	347%
Other Revenues	650,678		
Property and Equipment	831,162		
Research and Development	161,215		
Selling, General and Administrative Expense	271,224		